蛋白尿：减少还是支持阿巴西普治疗蛋白尿性肾病？
Proteinuria: abate or applaud abatacept in proteinuric kidney disease?
机构信息
Department of Medicine, Rush University Medical Center, 1735 West Harrison Street, Cohn Building, Suite 724, Chicago, IL 60612, USA.
Department of Medicine, Johns Hopkins University School of Medicine, Johns Hopkins Hospital, 600 Wolfe Street, Brady 502, Baltimore, MD 21287, USA.
出版信息
Nat Rev Nephrol. 2014 Mar;10(3):128-30. doi: 10.1038/nrneph.2013.276. Epub 2013 Dec 24.
T-lymphocyte activation antigen CD80 is a B-cell costimulator and podocyte injury marker originally described in lupus nephritis; CD80 blockade with abatacept disappointed in a lupus nephritis trial. A study now suggests abatacept efficacy in focal and segmental glomerulosclerosis. Small patient numbers and concurrent treatment regimens call for more definitive studies regarding this therapeutic strategy.
T 淋巴细胞活化抗原 CD80 是一种 B 细胞共刺激剂和足细胞损伤标志物，最初在狼疮肾炎中描述；阿巴西普阻断 CD80 的治疗在狼疮肾炎试验中令人失望。一项研究表明阿巴西普在局灶节段性肾小球硬化症中的疗效。患者数量少且同时进行治疗方案，这需要对这种治疗策略进行更明确的研究。
Zotero 插件